迈普医学
(301033)
| 流通市值：29.79亿 | | | 总市值：35.38亿 |
| 流通股本：5693.51万 | | | 总股本：6763.10万 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 294,321,686.63 | 189,801,626.51 | 78,362,845.65 | 368,830,564.59 |
| 营业总成本 | 198,969,081.21 | 128,608,088.16 | 57,213,511.8 | 255,227,189.08 |
| 其他经营收益 | | | | |
| 营业利润 | 103,914,255.31 | 67,137,460.69 | 23,763,550.87 | 128,009,555.2 |
| 利润总额 | 103,185,945.56 | 66,564,698.97 | 23,766,012.6 | 126,172,398.87 |
| 净利润 | 90,399,783.84 | 56,580,533.57 | 20,715,382.12 | 113,128,438.52 |
| 每股收益 | | | | |
| 其他综合收益 | -114,498.01 | -88,615.72 | -67,015.5 | 75,537.46 |
| 综合收益总额 | 90,285,285.83 | 56,491,917.85 | 20,648,366.62 | 113,203,975.98 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 408,209,517.11 | 361,368,462.18 | 378,251,049.86 | 375,194,183.32 |
| 非流动资产: | | | | |
| 非流动资产合计 | 548,547,752.79 | 539,934,277.19 | 529,576,902.94 | 520,242,380.04 |
| 资产总计 | 956,757,269.9 | 901,302,739.37 | 907,827,952.8 | 895,436,563.36 |
| 流动负债: | | | | |
| 流动负债合计 | 42,541,319.74 | 38,167,492.64 | 34,649,477.7 | 51,567,203.05 |
| 非流动负债: | | | | |
| 非流动负债合计 | 50,293,041.97 | 51,648,868.4 | 53,215,038.77 | 45,810,209.04 |
| 负债合计 | 92,834,361.71 | 89,816,361.04 | 87,864,516.47 | 97,377,412.09 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 863,922,908.19 | 811,486,378.33 | 819,963,436.33 | 798,059,151.27 |
| 股东权益合计 | 863,922,908.19 | 811,486,378.33 | 819,963,436.33 | 798,059,151.27 |
| 负债和股东权益合计 | 956,757,269.9 | 901,302,739.37 | 907,827,952.8 | 895,436,563.36 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 332,313,710.47 | 210,222,268.34 | 94,586,220.96 | 414,731,077.08 |
| 经营活动现金流出小计 | 243,044,245.25 | 162,019,680.43 | 91,383,995.96 | 274,864,398.51 |
| 经营活动产生的现金流量净额 | 89,269,465.22 | 48,202,587.91 | 3,202,225 | 139,866,678.57 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 428,692,378.1 | 258,457,876.45 | 123,096,868.62 | 560,430,012.07 |
| 投资活动现金流出小计 | 444,002,531.14 | 237,825,848.5 | 83,893,494.85 | 706,045,568.8 |
| 投资活动产生的现金流量净额 | -15,310,153.04 | 20,632,027.95 | 39,203,373.77 | -145,615,556.73 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 14,416,251.2 | - | - | 12,626,905.05 |
| 筹资活动现金流出小计 | 46,829,609.28 | 46,778,205.9 | - | 40,822,373.55 |
| 筹资活动产生的现金流量净额 | -32,413,358.08 | -46,778,205.9 | - | -28,195,468.5 |
| 汇率变动对现金及现金等价物的影响 | -883,559.18 | -648,129.59 | -360,776.12 | 321,959.72 |
| 现金及现金等价物净增加额 | 40,662,394.92 | 21,408,280.37 | 42,044,822.65 | -33,622,386.94 |
| 期末现金及现金等价物余额 | 60,257,609.25 | 41,003,494.7 | 61,640,036.98 | 19,595,214.33 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 21,408,280.37 | - | -33,622,386.94 |
最新报告期：2026-10-26| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 平安证券 | 叶寅,倪亦道,裴晓鹏 | 2.15 | 2.67 | 3.27 | 2026-10-26 |
| 广发证券 | 王稼宸,罗佳荣 | 2.17 | 3.04 | 4.49 | 2026-10-23 |
| 中信建投 | 刘慧彬,王在存,贺菊颖 | 2.09 | 2.62 | 3.24 | 2026-09-30 |
| 华创证券 | 郑辰,张良龙,李婵娟 | 2.15 | 2.91 | 3.92 | 2026-09-17 |
| 平安证券 | 叶寅,倪亦道,裴晓鹏 | 2.16 | 2.69 | 3.29 | 2026-08-24 |